Background-To evaluate the effect of inhaled /P2 adrenergic agonists on the sensitivity of airway cough receptors, the effect of inhaled procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects. Method-Eleven patients with asthma and 10 with chronic bronchitis and 14 normal subjects participated. Increasing concentrations of capsaicin solution were inhaled for 15 seconds by tidal breathing through the mouth at one minute intervals until five or more coughs were elicited, before and 30 minutes after inhalation of 20 ug procaterol or placebo (freon gas alone) through a metered dose inhaler. 
sensitivity of airway cough receptors, the effect of inhaled procaterol on cough induced by aerosolised capsaicin, a stimulant of C fibres, was studied in patients with asthma or chronic bronchitis and in normal subjects. Method-Eleven patients with asthma and 10 with chronic bronchitis and 14 normal subjects participated. Increasing concentrations of capsaicin solution were inhaled for 15 seconds by tidal breathing through the mouth at one minute intervals until five or more coughs were elicited, before and 30 minutes after inhalation of 20 ug procaterol or placebo (freon gas alone) through a metered dose inhaler. Cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs. To evaluate the bronchodilator effect of procaterol and the bronchoconstrictor effect of inhaled capsaicin, forced expiratory volume in one second (FEV,) was measured before and one minute after a capsaicin provocation test. This test was carried out both before and 30 minutes after treatment with procaterol or placebo. Results-The geometric mean value of cough threshold to capsaicin was significantly increased by procaterol and placebo in both groups of patients but not in the control subjects. The The study was carried out when symptoms were mild and stable, with patients taking only oral theophylline or oral and aerosol fl2 agonists with or without mucolytic agents. They had not received inhaled or oral steroids for at least eight weeks. All drug treatment was stopped at 9 pm on the previous day to allow a washout time of at least 12 hours before measuring cough threshold to inhaled capsaicin between 9 30 and 12 noon on the test day.
ASSESSMENT OF COUGH RECEPTOR SENSITIVITY TO INHALED CAPSAICIN
Capsaicin (30 5 mg) was dissolved in Tween 80 (1 ml) and ethanol (1 ml) and then dissolved in physiological saline (8 ml) to make a stock solution of 10 mmolIl, which was stored at -20°C. This solution was diluted with physiological saline to make solutions starting at a concentration of 0 49 umol/l and increasing by doubling concentrations up to 1 mmolIl. Each subject inhaled a control solution of physiological saline followed by progressively increasing concentrations of the capsaicin solution. The nose was clipped and solutions were inhaled for 15 seconds every 60 seconds from a Bennett Twin nebuliser (Puritan-Bennett, Carlsbad, California) through the mouth during tidal breathing. Increasing concentrations were inhaled until five or more coughs were elicited. The nebuliser output was 0-21 ml/min. Cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs. difference between changes in the cough threshold by procaterol and placebo the ratios of the cough threshold after these treatments to the baseline cough threshold were compared by a paired t test. A p value of 0 05 or less was taken as significant.
Results
FEV, and forced vital capacity before the first capsaicin challenge on the placebo day were 73% (7%) and 97% (5%) of predicted values in the asthmatic patients, 90% (5%) and 104% (4%) in the patients with chronic bronchitis, and 95% (3%) and 98% (4%) in the normal subjects. Figure 1 shows the cough threshold to inhaled capsaicin before and after the inhalation of 20 pg procaterol or placebo in the patients with asthma. Geometric mean values of cough threshold to inhaled capsaicin before the inhalation of procaterol and placebo were 8-85 umolI (1 -48) and 7-33 4umol/l (1 56), with no significant difference between them. The cough threshold was significantly increased by procaterol and placebo to ,umol/l (1.48), (p < 001) and 13-3 umolI (1.69), (p < 0 005), respectively. old before and after inhalation of procaterol or placebo in the normal subjects. 14) of placebo FEV1 was significantly decreased by capsaicin inhalation in the patients with chronic bronchitis but not in the asthmatic 2 shows the capsaicin cough thresh-patients or the normal subjects (table 2) . old before and after procaterol or placebo in the patients with chronic bronchitis. The geometric mean values before procaterol and placebo were (1-52) and ,umol/l (1-29), and these values were not significantly different. The cough threshold was significantly increased by procaterol and placebo to 14-6 ,umol/l (1-44) (p < 0-01) and 16-7 7mol/ (1.33) (p < 0-05), respectively. Figure 3 shows the capsaicin cough thresh-
Discussion
Cough usually results from the stimulation of sensory nerves in the airway.'0 The larynx has two types of cough receptors: myelinated irregularly firing irritant receptors" and non-myelinated C fibre nerve endings.'2 The tracheobronchial tree also has two types of cough receptors: myelinated rapidly adapting In our study inhaled procaterol at a dose of 20 ,ug, which was considered sufficient to reduce bronchomotor tone, significantly increased the cough threshold in the asthmatic and the bronchitic patients but not in the normal subjects. However, inhaled placebo also increased the cough threshold in both patient groups. We therefore compared the increment in the cough threshold after procaterol with that after placebo (fig 4) and there were no differences. Thus we conclude that inhaled procaterol has no effect on sensitivity of airway cough receptors to inhaled capsaicin in asthma and chronic bronchitis or in normal subjects.
The reproducibility of the dose-response curve for cough induced by capsaicin when challenges are performed at an interval of greater than 15 minutes is well established in normal subjects. 20 We have confirmed these findings in our study, in which the challenges were performed 30 minutes apart. In contrast, in patients with asthma and with chronic bronchitis we have shown that the cough threshold is increased when capsaicin challenges are performed 30 minutes apart. As this change in cough threshold occurred when placebo was inhaled we believe that it is due to tachyphylaxis to the tussive effects of capsaicin.
We used the FEV, to evaluate the bronchodilator effect of procaterol and the bronchoconstrictor effect of the cough threshold dose of capsaicin. Inhaled capsaicin significantly decreased FEV, at this threshold dose in the patients with asthma and chronic bronchitis. Inhalation of procaterol significantly increased FEV, in the patients with asthma and chronic bronchitis and in the normal subjects. Furthermore, inhaled procaterol inhibited the fall in FEV, induced by capsaicin inhalation. Consequently, we believe that inhalation of 20 ug procaterol is sufficient to produce bronchodilatation and to inhibit bronchoconstriction but not cough induced by capsaicin.
